350 rub
Journal Technologies of Living Systems №3 for 2012 г.
Article in number:
Immunohistochemical expression of gelatin-3 and e-cadherin in different immunophenotypic variants of gastric cancer
Keywords: gastric cancer immunohistochemistry mucins CD10 galectin-3 E-cadherin
Authors:
L.E. Gaganov, I.A. Kazantseva, L.E. Gurevich, E.I. Ustinova
Abstract:
The analysis of the parameters analyzed immunohistochemical expression of galectin-3 and E-cadherin in different carcinomas of the stomach immunophenotypic variants, differing in the expression of MUC1, MUC2, MUC5AS, MUC6, and CD10. The results are compared with indicators of four-year adjusted progression-free survival of operated patients. We found a significant correlation honey indicators for galectin-3 and immunophenotype of gastric cancer. In carcinomas with gastric immunophenotype of tumor cells overexpressing galectin-3 was higher than in tumors with mixed IPhT. The number of tumor cells expressing E-cadherin, in the studied variants of cancer not significantly different. We have established a significant correlation between indices of galectin-3, E-cadherin and survival rates. In carcinomas of living at the time of monitoring patients, indicators for galectin-3 and E-cadherin surpassed, similar parameters in the group died.
Pages: 28-31
References
  1. Kabashima A., Yao T., Sugimachi K., Tsuneyo­shi M. Gastric or intestinal phenotypic expression in the carcinomas and background mucosa of multiple early gastric carcinomas // Histopathology. 2000. V. 37. № 6. P. 513 - 522.
  2. Shiroshita H., Watanabe H., Ajioka Y. et al. Re-evaluation of mucin phenotypes of gastric minute well-differentiated type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains // Pathol. Int. 2004. V. 54. № 5. P. 311 - 321.
  3. Namikawa T., Hanazaki K. Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma // World J.
    Gastroenterol. 2010. № 36. P. 4634 - 4639.
  4. Toki F., Takahashi A., Aihara R. et al.Relationship between clinicopathological features and mucin phenotypes of advanced gastric adenocarcinoma // World J. Gastroenterol. 2010.
    № 22. P. 2764 - 2770.
  5. Гаганов Л.Е., Казанцева И.А., Гуревич Л.Е., Корсакова Н.А.Отдаленные результаты хирургического лечения различных иммунофенотипических вариантов рака желудка // Хирург. 2011. № 11. С. 20 - 24.
  6. Wakatsuki K., Yamada Y., Narikiyo M. et al. Clinicopathological and prognostic significance of mucin phenotype in gastric cancer // J. Surg. Oncol. 2008. V. 98. № 2. P. 124 - 129.
  7. Balan V., Nangia-Makker P., Raz A. Galectins as cancer biomarkers // Cancer. 2010. V. 2. № 2. P.592 - 610.
  8. Krzeslak A., Lipinska A. Galectin-3 as a multifunctional protein // Cell. Mol. Biol. Lett. 2004. V. 9. № 2. P. 305 - 328.
  9. Chan A.O.O. E-cadherin in gastric cancer // World J. Gastroenterol. 2006. № 2. Р. 199 - 203.
  10. Cheong T., Shin J., Chun K. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents // Cancer Sci. 2010. V. 101. № 1. P.94 - 102.
  11. Okada K., Shimura T., Suehiro T. et al.Reduced galectins-3 expression is an indicator of unfavorable prognosis in gastric cancer // Anticancer Res. 2006. V. 26. № 2В. P. 1369 - 1376.
  12. Zali M.R., Moaven O., Adhdaee H.A. et al.Clinicopathological significance of E-cadherin, β-catenin and p53 expression in gastric adenocarcinoma // J. Res. Med. Sc. 2009. V. 14. № 4. P. 239 - 247.
  13. Гаганов Л.Е., Казанцева И.А., Гуревич Л.Е., Корсакова Н.А. Особенности экспрессии Е-кад­херина в карциномах желудка // Альманах клинической медицины. 2011. № 24. С. 3 - 8.